AnaptysBio Inc reports results for the quarter ended in March - Earnings Summary

AnaptysBio

09/05/2024 23:16

* AnaptysBio Inc  ANAB.OQ  reported a quarterly adjusted
loss of
$1.64​​ per share for the quarter ended in March, lower than the
same quarter last year, when the company reported EPS of
$-1.58.  The mean expectation of eleven analysts for the quarter
was for a loss of $1.57 per share. Wall Street expected
results to range from $-1.90 to $-1.41 per share.
    * Revenue rose 422.5% to $7.18 million from a year ago;
analysts
expected $3.97 million. 
    * AnaptysBio Inc's reported EPS for the quarter was a loss
of
$1.64​.
    * The company reported a quarterly loss of $43.94 million.
    * AnaptysBio Inc shares had risen by 14.3% this quarter and
gained 20.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4.5%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for AnaptysBio Inc is
$47.00 
This summary was machine generated from LSEG data May 9 at 10:15
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.57          -1.64          Missed
 Dec. 31 2023      -1.60          -1.59          Beat
 Sep. 30 2023      -1.79          -1.41          Beat
 Jun. 30 2023      -1.70          -1.50          Beat